Because CML pathogenesis is heavily dependent on the p210 isoform of the BCR::ABL1, this protein also serves as an attractive target for therapies such as tyrosine kinase inhibitors (TKI). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.